PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: LUDWIG Dale L. Group Art Unit: 1643

Patent No.: 7,638,605 Examiner: Blanchard, David J

Issue Date: December 29, 2009

Serial No.: 10/555407

Filed: May 3, 2004

PCT Nat'l Entry

Date (if applicable): November 1, 2005

371 Date: June 8, 2007

Title: FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE

HUMAN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR

Docket No.: X18524

REQUEST FOR RECONSIDERATION OF PATENT TERM ADJUSTMENT INDICATED AT ISSUANCE (37 C.F.R. § 1.705(d))

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Patentee submits this Request for Reconsideration of Patent Term Adjustment under 37 C.F.R. § 1.705(d) in the above-referenced issued patent, accompanied by the requisite fee under 37 C.F.R. § 1.18(e). Patentee believes that no additional fees are due with the filing of this Request. However, if any fees are required, Patentee hereby authorizes the Commissioner to charge such fee, or credit any overpayment in fees, to Deposit Account No. 05-0840.

REMARKS

Patentee hereby petitions the U.S. Patent and Trademark Office for reconsideration of the Patent Term Adjustment ("PTA") calculation. Applicants received Notice of Issuance from the U.S. Patent and Trademark Office, mailed on December 9, 2009, with notification that the Patent Term Adjustment under 35 U.S.C. §154(b) is 263 days. It is the Patentee's position that the PTA calculation should be amended to 455 days based on the facts provided herein. This PTA request is

submitted in view of the decision by the U.S. Court of Appeals for the Federal Circuit in *Wyeth v. Kappos*, 591 F.3d 1364 (Fed. Cir., 2010) and the "Notice Concerning Calculation of the Patent Term Adjustment under 35 U.S.C. § 154(b)(1)(B) involving International Applications Entering the National Stage Pursuant to 35 U.S.C. § 371" issued on September 9, 2009.

There are no issues that were raised or could have been raised in the application pertaining to patent term adjustment under 37 C.F.R § 1.705(b) before the patent issued. This request for patent term adjustment raises new issues that could only be raised following the issuance of the patent, which fully complies with 37 C.F.R § 1.705(b)(2)(iv)(A). This petition is filed within two months of the date the patent issued in accordance with 37 C.F.R § 1.705(d).

BACKGROUND

According to the provisions of 35 U.S.C. § 154(b)(1)(B) and 37 C.F.R. § 1.702(b), Applicants are entitled to PTA for the failure of the Office to issue a patent within three years after the actual filing date of the application in the United States. Pendency of the application should be measured from the filing date which is the date that "the national stage" commenced under 35 U.S.C. § 371(b) or (f). Delays in prosecution legitimately attributable to applicant or failure of the applicant to engage in reasonable efforts to conclude processing or examination of the application as set forth in 37 C.F.R. § 1.704(b) should be subtracted from the total PTA calculation. A patentee is entitled to both "A Delay" and "B Delay" to the extent that the "A Delay" and "B Delay" terms do not occur on the same calendar day. *Wyeth v. Kappos*, 591 F.3d 1364, 1370 (Fed. Cir., 2010).

STATEMENT OF FACTS

1. The present application is a national stage filing under 35 U.S.C. § 371 of international application number PCT/US2004/013852, filed May 3, 2004, claiming priority of U.S. Provisional Application No. 60/467,177, filed May 1, 2003. *See* Exhibit 2.

- 2. The national stage for the present application was filed on November 1, 2005. *See* Exhibit 2.
- 3. A notice of missing parts regarding the oath/declaration was mailed on January 16, 2007. See Exhibit 3.
- 4. The response to the notice of missing parts was filed on June 8, 2007. *See* Exhibits 1 and 4.
- 5. The requirements of 35 U.S.C. § 371 were fulfilled on June 8, 2007. *See* Exhibits 1 and 4.
- 6. The PTO mailed the first non-final Office Action on April 28, 2009. *See* Exhibits 1 and 5.
- 7. The Notice of Allowance was mailed on August 10, 2009. *See* Exhibits 1 and 6.
- 8. The Notice of Allowance cited 263 days of PTA. See Exhibit 6.
- 9. The Issue Fee was paid on November 10, 2009. See Exhibits 1 and 7.
- 10. Notice of Issuance mailed on the December 9, 2009, with notification that the Patent Term Adjustment is 263 days. *See* Exhibits 1 and 8.
- 11. US Patent No. 7,638,605 issued on December 29, 2009. See Exhibits 1 and 8.

THE ACTUAL FILING DATE OF A U.S. NATIONAL STAGE APPLICATION FILED UNDER 35 U.S.C. § 371 IS 30 MONTHS FROM THE PRIORITY DATE

Patentee respectfully submits that the Office did not apply the proper standard for determining the period of "B Delay" under 35 U.S.C. § 154(b)(1)(B). It is the patentee's understanding that the Office measured application pendency as beginning on June 8, 2007, the date on which the application fulfilled the requirements of 35 U.S.C. § 371. However, as detailed below, the relevant statutes and regulations state that when calculating "B Delay" for a national stage filing under 35 U.S.C. § 371, application pendency must be measured from the date that is 30 months from the priority date of the international application, not from the date on which the application fulfilled the requirements of 35 U.S.C. § 371 as stated in the "Notice Concerning Calculation of the Patent Term Adjustment under 35 U.S.C. § 154(b)(1)(B) involving International Applications Entering the National Stage Pursuant to 35 U.S.C. § 371" issued on September 9, 2009.

The term of a patent shall be extended if the Office fails to issue a patent within three years after the "actual filing date" of the application.

Subject to the limitations under paragraph (2), if the issue of an original patent is delayed due to the failure of the United States Patent and Trademark Office to issue a patent within 3 years after the <u>actual filing date</u> of the application in the United States . . . the term of the patent shall be extended 1 day for each day after the end of that 3-year period until the patent is issued.

35 U.S.C. § 154 (b)(l)(B) (emphasis added). 37 C.F.R. §1.702(b) explains the meaning of the term "actual filing date" as set forth in 35 U.S.C. § 154(b)(l)(B). As detailed below, PTO delay for a national stage application begins if the Office fails to issue a patent within three years after the date the national stage "commenced under 35 U.S.C. 371(b) or (f)."

Failure to issue a patent within three years of the <u>actual filing date</u> of the application. Subject to the provisions of 35 U.S.C. 154(b) and this subpart, the term of an original patent shall be adjusted if the issuance of the patent was delayed due to the failure of the Office to issue a patent within three years after the date on which the application was filed under 35 U.S.C. 111(a) or <u>the national stage commenced under 35 U.S.C. 371(b) or (f)</u> in an international application...

37 C.F.R. § 1.702(b) (emphasis added).

35 U.S.C. § 371(b) states that a national stage application "commences" "with the expiration of the applicable time limit under article 22 (1) or (2), or under article 39 (l)(a) of the treaty." 35 U.S.C. § 371 (f) states that "at the express request of the applicant, the national stage of processing may be commenced at any time at which the application is in order for such purpose and the applicable requirements of subsection (c) of this section have been complied with."

In the instant case, Applicants filed under 35 U.S.C. § 371(b). Under the provisions of 35 U.S.C. § 371(b), the U.S. national stage commences after the expiration of the applicable time limit under article 22(1) or (2), or under article 39(1)(a) of the treaty. The "applicable time limit" referred to in Patent Cooperation Treaty articles 22(1), 22(2), and 39(1)(a) is "the expiration of 30 months from the priority date."

[I]n the absence of an express request for early processing of an international application under 35 U.S.C. 371(f) and compliance with the conditions provided therein, the <u>U.S. national stage will commence upon expiration of 30 months from the priority date of the international application</u>.

MPEP § 1893.01 (emphasis added).

It appears that in a similar petition filed in U.S. Patent 7,465,444, the Office recognized that for the purposes of calculating "B Delay" for a national stage filing under 35 U.S.C. § 371, application pendency is measured from the date that is 30 months from the priority date of the international application. *See* Exhibit 9, "Decision On Request For Reconsideration of Patent Term Adjustment" page 2 paragraph 4.

B DELAY IS CALCULATED FROM THE "ACTUAL FILING DATE"

The patentee respectfully submits that the "actual filing date" of a U.S. national stage application filed under 35 U.S.C. § 371(b), for purposes of calculating "B Delay" under 35 U.S.C. § 154(b)(l)(B) and 37 C.F.R. § 1.702(b), is the date that is 30 months from the priority date of the international application. Accordingly, the actual filing date of U.S. Patent No. 7,638,605 is November 1, 2005. Therefore, the "actual filing date" for purposes of calculating "B Delay" in the instant application should be revised from June 8, 2007 to November 1, 2005.

The patentee respectfully requests that the "B Delay" be recalculated to account for the foregoing, in light of the decision by the U.S. Court of Appeals for the Federal Circuit decision in *Wyeth v. Kappos*, 591 F.3d 1364 (Fed. Cir., 2010) and the "Notice Concerning Calculation of the Patent Term Adjustment under 35 U.S.C. § 154(b)(1)(B) involving International Applications Entering the National Stage Pursuant to 35 U.S.C. § 371". The Federal Circuit in *Wyeth* held that a patentee is entitled to both "A Delay" and "B Delay" to the extent that the "A Delay" and "B Delay" terms do not occur on the same calendar day. *See id.* at 1370. Since the above referenced application was filed on November 1, 2005 and did not issue until December 29, 2009, this application was pending longer than three years after the actual filing date. "B Delay" should therefore be recalculated as set forth below in accordance with 35 U.S.C. § 154 (b)(l)(B).

REVIEW AND RECALCULATION OF PATENT TERM ADJUSTMENT

"A DELAY"

The PTO calculated an "A Delay" of 263 days. Applicant does not dispute this calculation. A first PTO action mailed on or after August 9, 2008, the day after the date that is fourteen months after the date on which the application fulfilled the requirements of 35 U.S.C. § 371 (which in the instant case is June 8, 2007), would trigger the start of the "A Delay." See 37 C.F.R. § 1.703(a)(1). In the instant case, the PTO mailed the first non-final Office Action on April 28, 2009, thereby accumulating a PTO Delay of 263 days. Accordingly, the patentee agrees that the "A Delay" calculated by the PTO from the period beginning August 9, 2008 (the day after the end of the fourteen month deadline) to April 28, 2009 was correctly determined by the PTO to be 263 days.

"B DELAY"

The "B Delay" in the instant patent should be 423 days. The present patent issued from an application that is a national stage filing under 35 U.S.C. § 371 of international application number PCT/US2004/013852, filed May 3, 2004, which claims priority of U.S. Provisional Application No. 60/467,177, filed May 1, 2003. First, the national stage for the present patent "commenced" under the provisions of 35 U.S.C. § 371(b), on November 1, 2005, which is 30 months from the priority date of May 1, 2003. *See* 35 U.S.C. § 154(b)(1)(B).

"B Delay" commenced on November 2, 2008, the day after three years from the actual filing date of November 1, 2005, and ended on the date the patent issued, December 29, 2009. *See* 37 C.F.R. § 1.703(b). This term is 423 days in length.

The PTO incorrectly calculated the "B Delay" term based on the fulfillment of the 35 C.F.R. § 371 obligations, rather than from the actual filing date of the application as required by 37 C.F.R. § 1.702(b). As a result, the PTO's calculation of "B Delay" is incorrect and lead to an erroneous finding of 0 days of "B Delay." The correct PTO "B Delay" for issuance of the patent after three years from filing is 423 days. See 37 C.F.R. §§ 1.702(b) and 1.703(b).

OVERLAP OF "A DELAY" AND "B DELAY"

As detailed above, "A Delay" accumulated during the following period: August 09, 2008, to April 28, 2009. This is a total of 263 days.

As detailed above, "B Delay" accumulated during the following period: November 02, 2008, to December 29, 2009. This is a total of 423 days.

The "A Delay" and "B Delay" terms overlap from November 02, 2008 to April 28, 2009. This is a total of <u>178 days</u>.

APPLICANT DELAY

Delay in submitting an oath or declaration in response to a Notice of Missing Parts could constitute a failure to engage in reasonable efforts to conclude processing or examination of the application as set forth 37 C.F.R. § 1.704.

With respect to the grounds for adjustment set forth in §§ 1.702(a) through (e), and in particular the ground of adjustment set forth in § 1.702(b), an applicant shall be deemed to have failed to engage in reasonable efforts to conclude processing or examination of an application for the cumulative total of any periods of time in excess of three months that are taken to reply to any notice or action by the Office making any rejection, objection, argument, or other request, measuring such three-month period from the date the notice or action was mailed or given to the applicant, in which case the period of adjustment set forth in § 1.703 shall be reduced by the number of days, if any, beginning on the day after the date that is three months after the date of mailing or transmission of the Office communication notifying the applicant of the rejection, objection, argument, or other request and ending on the date the reply was filed. The period, or shortened statutory period, for reply that is set in the Office action or notice has no effect on the three-month period set forth in this paragraph.

37 C.F.R. § 1.704(b). A notice of missing parts was mailed on January 16, 2007. Under 37 C.F.R. § 1.704, applicants were required to respond to the objection by April 16, 2007 which corresponds to three months from the notice. The response to the notice of missing parts was filed on June 8, 2007. A period of <u>53 days</u> occurred between April 17, 2007, the day following the three month response period, and June 8, 2007, the date of filing of the oath / declaration.

TERMINAL DISCLAIMER

This patent is not subject to a terminal disclaimer.

TOTAL PTA

Serial No. 10/555407

Total PTA should be calculated as 455 days, not 263 days:

1) Total PTO Delay should be calculated as <u>508 days</u>. This represents the sum of

263 days of 37 C.F.R. § 1.702(a) or "A Delay" and 423 days of 37 C.F.R. §

1.702(b) or "B Delay" minus 178 days of overlapping "A Delay" and "B

Delay");

2) Total PTO Delay under 37 C.F.R. § 1.702(c)-(e) should be calculated as <u>0</u>

days;

3) Total Applicant Delay under 37 C.F.R. § 1.704 should be calculated as <u>53</u>

days; and

4) Total PTA should be calculated as 455 days. This represents 508 days of PTO

Delay minus 53 days of Applicant Delay.

CONCLUSION

In consideration of the events described above, and in light of the recent

Federal Circuit Wyeth decision and the "Notice Concerning Calculation of the Patent

Term Adjustment under 35 U.S.C. § 154(b)(1)(B) involving International

Applications Entering the National Stage Pursuant to 35 U.S.C. § 371", the total PTA

calculation should be 455 days, not 263 days. As such, Patentee respectfully requests

reconsideration of the PTA.

Respectfully submitted,

/Nicole S. Woods/

Nicole S. Woods

Attorney for Applicant

Registration No. 56,579

Phone: 908-203-6835

Eli Lilly and Company **Patent Division**

P.O. Box 6288

Indianapolis, Indiana 46206-6288

February 26, 2010

8

Exhibit 1

Transaction	History
Date	Transaction Description
02-02-2010	Sequence Moved to Public Database
12-29-2009 12-10-2009	Recordation of Patent Grant Mailed Email Notification
12-09-2009	Issue Notification Mailed
12-29-2009 11-13-2009	Patent Issue Date Used in PTA Calculation Dispatch to FDC
11-13-2009	Application Is Considered Ready for Issue
11-10-2009 11-10-2009	Issue Fee Payment Verified Issue Fee Payment Received Converse Formanded to Bulko on Tana
08-24-2009 08-11-2009	Sequence Forwarded to Pubs on Tape Electronic Review
08-10-2009 08-10-2009	Email Notification Email Notification
08-10-2009	Mail Examiner's Amendment
08-10-2009 08-04-2009	Mail Notice of Allowance Document Verification
08-04-2009 08-04-2009 08-03-2009	Notice of Allowance Data Verification Completed Case Docketed to Examiner in GAU Examiner's Amendment Communication
08-03-2009	Email Notification
08-03-2009 07-28-2009	Mail Examiner Interview Summary (PTOL - 413) Examiner Interview Summary Record (PTOL - 413)
12-23-2008	Information Disclosure Statement considered
12-23-2008 05-29-2009	Information Disclosure Statement considered Date Forwarded to Examiner
05-28-2009 04-28-2009	Response to Election / Restriction Filed Electronic Review
04-28-2009 04-28-2009	Email Notification Mail Restriction Requirement
04-24-2009 12-23-2008	Requirement for Restriction / Election Electronic Information Disclosure Statement
12-23-2008 03-12-2009	Electronic Information Disclosure Statement Email Notification
03-12-2009 03-12-2009 03-06-2009	Change in Power of Attorney (May Include Associate POA) Correspondence Address Change
12-23-2008	Information Disclosure Statement (IDS) Filed
12-23-2008 06-25-2008	Information Disclosure Statement (IDS) Filed Change in Power of Attorney (May Include Associate POA)
06-24-2008	Correspondence Address Change
03-01-2008 11-01-2005	Case Docketed to Examiner in GAU Request for Foreign Priority (Priority Papers May Be Included)
01-31-2008	PG-Pub Issue Notification
11-01-2007 11-01-2005	Miscellaneous Incoming Letter Preliminary Amendment
11-11-2007	Application Dispatched from OIPE
10-31-2007 10-25-2007	Change in Power of Attorney (May Include Associate POA) Correspondence Address Change

06-08-2007	371 Completion Date
08-21-2007	Sent to Classification Contractor
08-21-2007	Notice of DO/EO Acceptance Mailed
06-08-2007	Additional Application Filing Fees
06-08-2007	A statement by one or more inventors satisfying the requirement under 35 USC 115, Oath of the Applic
05-18-2006	Cleared by OIPE CSR
11-17-2005	CRF Is Good Technically / Entered into Database
11-01-2005	CRF Disk Has Been Received by Preexam / Group / PCT
11-01-2005	Initial Exam Team nn

Close Window

Exhibit 2

	¢ .	JC10 Re	C'HPCT/PTO O 1 NOV 2005
FORM PT	9-1390 U.S. DEPARTMENT OF COM	MERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TR	ANSMITTAL LETTE DESIGNATED/ELEC	R TO THE UNITED STATES TED OFFICE (DO/EO/US)	11245/53202
	CONCERNING A FIL	ING UNDER 35 U.S.C. 371	To Be Assigned 555457
INTERN	ATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED:
PCT/U	S2004/013852	03 May 2004	01 May 2003
TITLEO	FINVENTION		
FULL' RECE		RECTED AGAINST THE HUMAN INS	ULIN-LIKE GROWTH FACTOR-1
APPLICA	NT(S) FOR DO/EO/US		
***********	LUDWIG		
Applica	int herewith submits to the United	d States Designated/Elected Office (DO/EO/U	S) the following items and other information:
1. 🗹	This is a FIRST submission of	items concerning a filing under 35 U.S.C. 37	
2.		QUENT submission of items concerning a fili	
3. 🗹		gin national examination procedures (35 U.S.)	
4. 🖾	The US has been elected (Artic		
s. Ø	,	olication as filed (35 U.S.C. 371(c)(2))	
O S ANDRE		ed only if not communicated by the Internation	nal Bureau).
	b. Chas been communicated by	· · · · · · · · · · · · · · · · · · ·	
		plication was filed in the United States Receiv	ino Office (RO/US)
6. 🗆		n of the International Application as filed (35)	-
Or think	a. \square is attached hereto.	i or me imerimanomia rippiremen as mee (20	Comment of a Continue of the C
		nitted under 35 U.S.C. 154(d)(4).	
7. O	•	ne International Application under PCT Articl	e 19 (35 U.S.C. 371(c)(3))
		ed only if not communicated by the Internation	
	b. \square have been communicated		
	•	ever, the time limit for making such amendme	nts has NOT expired.
	d. M have not been made and v	and the second s	-
8. 🗆		n of the amendments to the claims under PCT	Article 19 (35 U.S.C. 371(c)(3)).
9.		ventor(s) (35 U.S.C. 371(c)(4)). (Unsigned)	
10. 🗅		n of the annexes of the International Prelimina	ry Examination Report under PCT
Items 1	1 to 20 below concern documen	nt(s) or information included:	
11. 🗹	Preliminary Amendment.		
12. 🗆	An assignment document for re	cording. A separate cover sheet in compliance	e with 37 CFR 3.28 and 3.31 is included.
13. 🗀	An Information Disclosure Stat	ement under 37 CFR 1.97 and 1.98.	
14. 🗆	An Application Data Sheet und	er 37 CFR 1.76.	•
15. 🗆	A substitute specification.		
16. D	A power of attorney and/or cha	nge of address letter.	
17. D	A computer-readable form of the	ne sequence listing in accordance with PCT R	ule 13ter.2 and 37 CFR 1.821 - 1.825.
18.	A second copy of the published	l international application under 35 U.S.C. 15	4(d)(4).
19.	A second copy of the English la	anguage translation of the international applica	ation under 35 U.S.C. 154(d)(4).
20. 🗹		py of Published International Application; cor (18) pages) and computer readable form (one)	T T

CFR 1.5)					ATTORNEY'S DOC 11245/53202	KETNUMBER	
The fol	lowing	fees are s	ubmitte	ed:			
21 🗆 Basic Nat	ional Fe	£	o de la grada de quada de grada de	V.N.Y.N.Y.N.Y.Y.Y.Y.Y.Y.Y.Y.Y.Y.Y.Y.Y.Y.	.\$ 300.00	\$300.00	
				al preliminary exam			
				s satisfy provisions of			
CT Article 33/	(1)-(4)		en en de de de de de de de de	graphy graphy and have a find the state of t	S 100.00	\$	
·····	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	······································	·····	ions	·	\$200.00	
		7,		1.445(a)(2) has been	3		
	*********	······	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	he USPTO as ISA	\$ 100.00	3	
		•		red and provided to	\$ 400.00	\$400.00	
			******	######################################		\$ ************************************	
	7C - 7XII (Mich 200		**************************************	.13 200.00	, o	
тота	AL OF A	ABOVE	CALC	ULATIONS		\$900.00	
	······································	·····	·····	wings filed in paper over	100 sheets		
(excluding sequ	ence listi	ng on con	aputer p	rogram listing filed in an	electronic		
		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	*************	nal 50 sheets of paper or	· · · · · · · · · · · · · · · · · · ·	1	
Total Sheets	Extra	Sneets		er of each additional 50 or an athereof (round up to a	RATE		
			whole	number)			
-100	/50=		1		x \$250		
from the earlies			**	th or declaration later the CFR 1.492(e)).	in 30 months	¢.	
CLAIMS		NUM		NUMBER EXTRA	RATE	7	
CEANNO		FIL		140100011 07 1103	100110		
Total Claims	*****************	73	- 20 =	53	x \$50.00	2,650.00	
Independent Cla) }	5	. <u>]</u> ==	2	x \$200,00	\$400.00	
MULTIPLE DE	PENDE	NT CLAI	M(S) (if	applicable)	+ \$360.00	\$360.00	
			TO	TAL OF ABOVE CAL	CULATIONS =	\$	
Applicant above are:			status.	See 37 CFR 1.27. The f	ees indicated		
	***********				SUBTOTAL =	\$4,310.00	
Processing fee of from the earlies			-	e English translation late CFR 1.492(f)).	er than 30 months	S	
				TOTAL N	ational fee =	\$4,310.00	
be accompanied	by an ap			(37 CFR 1.21(h)). The aneet (37 CFR 3.28, 3.31).		\$	
\$40.00 per prop	CATA			TOTAL FERS	ENCLOSED ==	\$4,310.00	
				+ ~~ + 5 ~ * * * * * * * * * * * * * * * * * *	Comments to the time that hell that the time	Amount to be	\$
			***************************************			refunded:	
***************************************		······························	**********			Amount to be charged	\$
b. 🗹 Ple	ease charg	ge my De	posit Ac	count No. <u>11-0600</u> in the is enclosed.			ove fees.
d. D Fee	erpaymer es are to l	nt to Depo be charge	sit Acco	authorized to charge any ount No. 11-0600. A du edit card. WARNING: Included on this form. P	plicate copy of this	s sheet is enclosed. I form may become p	sublic. Credit card
	F	-7		it under 37 CFR 1.495 lethe application to pend	3 3	a petition to revive	(37 CFR 1.137(a) or
SEND ALL CO	~	NDENC			#IGNATURE	///	*************
One Bro	adway	*** York 100	ስል	4	Lawrence P. Cass	6n (Reg. No. 46.	606)
		NO. 26		•	Novembe	r 1 2000	neger L
		REV 10-20		2 of 2	DATE		

(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 24 February 2005 (24.02.2005)

PCT

(10) International Publication Number WO 2005/016970 A2

- (51) International Patent Classification?: C07K 16/28, A61K 39/395, A61P 35/00, C12N 15/13, 15/63, 5/10
- (21) International Application Number:

Ÿ

1,5

PCT/US2004/013852

(22) International Filing Date:

3 May 2004 (03.05.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/467,177

US 1 May 2003 (01.05.2003)

- (71) Applicant (for all designated States except US): IM-CLONE SYSTEMS INCORPORATED [US/US]; 180 Varick Street, New York, NY 10014 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): LUDWIG, Dale, L. [US/US]; 14 Lookout Road, Randolph, NJ 07869 (US).
- (74) Agents: SOMERVILLE, Deborah, A. et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ΣW
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE HUMAN INSULIN-LIKE GROWTH FACTOR-1 RE-**CEPTOR**

(57) Abstract: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.

005/016970

WO 2005/016970

FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE HUMAN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR

[0001] This application claims the benefit of United States Provisional Application 60/467,177, filed May 1, 2003.

BACKGROUND

[0002] The insulin-like growth factor receptor (IGF-IR) is a ubiquitous transmembrane tyrosine kinase receptor that is essential for normal fetal and post-natal growth and development. IGF-IR can stimulate cell proliferation, cell differentiation, changes in cell size, and protect cells from apoptosis. It has also been considered to be quasiobligatory for cell transformation (reviewed in Adams et al., Cell. Mol. Life Sci. 57:1050-93 (2000); Baserga, Oncogene 19:5574-81 (2000)). The IGF-IR is located on the cell surface of most cell types and serves as the signaling molecule for growth factors IGF-I and IGF-II (collectively termed henceforth IGFs). IGF-IR also binds insulin, albeit at three orders of magnitude lower affinity than it binds to IGFs. IGF-IR is a pre-formed hetero-tetramer containing two alpha and two beta chains covalently linked by disulfide bonds. The receptor subunits are synthesized as part of a single polypeptide chain of 180kd, which is then proteolytically processed into alpha (130kd) and beta (95kd) subunits. The entire alpha chain is extracellular and contains the site for ligand binding. The beta chain possesses the transmembrane domain, the tyrosine kinase domain, and a C-terminal extension that is necessary for cell differentiation and transformation, but is dispensable for mitogen signaling and protection from apoptosis.

[0003] IGF-IR is highly similar to the insulin receptor (IR), particularly within the beta chain sequence (70% homology). Because of this homology, recent studies have demonstrated that these receptors can form hybrids containing one IR dimer and one IGF-IR dimer (Pandini et al., Clin. Canc. Res. 5:1935-19 (1999)). The formation of hybrids occurs in both normal and transformed cells and the hybrid content is dependent upon the concentration of the two homodimer receptors (IR and IGF-IR) within the cell. In one study of 39 breast cancer specimens, although both IR and IGF-IR were over-expressed in all tumor samples, hybrid receptor content consistently exceeded the levels of both homo-receptors by approximately 3-fold (Pandini et al., Clin. Canc. Res. 5:1935-44 (1999)). Although hybrid receptors are composed of IR and IGF-IR pairs, the hybrids bind selectively to IGFs, with

Exhibit 3

05/01/2003



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. 800 1450
Alazandra, Vogicia 27315-1450
SW.upto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	PTEA	ATTY, DOCKET NO.	
10/555,407	Dale L. Ludwig	11	245/53202	
		INTERNATIONAL API	PLICATION NO.	
		PCT/US04/	13852	
26646		I.A. FILING DATE	PRIORITY DATE	

26646 KENYON & KENYON LLP ONE BROADWAY NEW YORK, NY 10004

CONFIRMATION NO. 7544
371 FORMALITIES LETTER

05/03/2004

OC000000021999062

Date Mailed: 01/16/2007

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 11/01/2005
- Copy of the International Search Report filed on 11/01/2005
- Preliminary Amendments filed on 11/01/2005
- Biochemical Sequence Diskette filed on 11/01/2005
- Biochemical Sequence Listing filed on 11/01/2005
- Request for Immediate Examination filed on 11/01/2005
- U.S. Basic National Fees filed on 11/01/2005
- Priority Documents filed on 11/01/2005

The applicant needs to satisfy supplemental fees problems indicated below.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath
 or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the
 missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

\$130 Surcharge.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

LAMONT M HUNTER

Telephone: (703) 308-9140 EXT 201

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/555,407	PCT/US04/13852	11245/53202

FORM PCT/DO/EO/905 (371 Formalities Notice)

Exhibit 4

********	*********	+++++						
TORN I	-2000)		ark office; u.s. department of commence	ATTORNEY'S DOCKET NUMBER				
		ANSMITTAL LETTER	TO THE UNITED STATES	1017.53202				
	I	DESIGNATED/ELECTE	D OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
(CON	ICERNING A SUBMISS	SION UNDER 35 U.S.C. 371	10/555,507				
NTE		ONAL APPLICATION NO. PCT/US2004/013852	INTERNATIONAL FILING DATE 3 May 2004	PRIORITY DATE CLAIMED 1 May 2003				
TITLE	OFI	NVENTION						
fULI	LY H	UMAN ANTIBODIES DIRECT	ED AGAINST THE HUMAN INSULIN-L	JKE GROWTH FACTOR-1 RECEPTOR				
VDD!	ICAN"	T(S) FOR DO/EO/US						
Oale:	L. Lu	dwig						
Applic	ant h	erewith submits to the United State	s Designated/Elected Office (DO/EO/US) the t	following items and other information:				
1.	\Box	This is a FIRST submission of iter	ms concerning a submission under 35 U.S.C.	374.				
2.	*	This is a SECOND or SUBSEQUI	ENT submission of items concerning a submis	ssion under 35 U.S.C. 371.				
3.		This is an express request to beginners and (25) indicated below.	in national examination procedures (35 U.S.C	. 371(f)). The submission must include items (5), (6),				
4.		The US has been elected (Articlé	31).					
S.	\square	A copy of the International Applica	ation as filed (35 U.S.C. 371 (c)(2))					
		a. III is attoched hereto (requ	ired only if not communicated by the Internati	onal Bureau).				
		b. 🔲 has been communicated	d by the International Bureau.					
		c. 🔲 is not required, as the a	pplication was filed in the United States Recei	ving Office (RO/US).				
8 .		An English language translation o	of the International Application as filed (35 U.S.	.C. 371(c)(2)).				
		a. 🗍 is attached hereto.						
		b. 🗀 has b ee n previously sub	omitted under 35 U.S.C. 154(d)(4).					
7.		Amendments to the claims of the	International Application under PCT Article 19	(35 U.S.C. 371 (c)(3))				
		a. 🗆 - are attached hereto (rec	quired only if not communicated by the Interna-	tional Bureau).				
		b. 🔲 have been communicate	ed by the International Bureau.					
		c. [] have not been made; ho	owever, the time limit for making such amends	nents has NOT expired.				
		d. 🖽 - Have not been made an						
8.		An English language translation of	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9.	×	An oath or declaration of the inve						
10.		An English language translation of Article 36 (35 U.S.C. 371 (c)(5)).	of the annexes to the International Preliminary	Examination Report under PCT				
11.	{:}	A copy of the International Prelim	inary Examination Report (PCT/IPEA/409).					
12.		A copy of the International Search	Report (PCT/ISA/210).					
H	ems 1	3 to 23 below concern document	i(s) or information included:					
13.	1}	An Information Disclosure States	nent under 37 CFR 1.97 and 1.98.					
14.		An assignment document for reco	ording. A separate cover sheet in compliance	with 37 CFR 3.28 and 3.31 is included.				
15 .		A FIRST preliminary amendment						
18.		A SECOND or SUBSEQUENT pr	eliminary amendment.					
17.		An Application Data Sheet under	37 CFR 1.76.					
18.	;	A substitute specification.						
19.		A power of attorney and/or chang						
20.			sequence listing in accordance with PCT Rule					
23.			nternational Application under 35 U.S.C. 154(r					
22.		A second copy of the English language translation of the international Application under 35 U.S.C. 154(d)(4).						

☐ Express Mail Label No.

23.

			ons ere required to respon	U .	Approv S. Patent and Trademañ	ed for use t COffice; U.3	PTO-1 hrough 3/31/200 3. DEPARTMEN	(390 (95v. 09-2006) 27. OMB 0651-0021 37 OF COMMERCE
Under the Papervor U.S. APPLICATION			ons are required to respon INTERNATIONAL PCT/US21	APPE	(CATION NO.		spłays a valió O EY'S DOCKET I	
24. Other item	s or information;	~~~~ ~~~~~~						•
	Three Month Ext			A	A STATE OF THE A STATE OF THE A			
Note chang	e of Humbey man	nenyon to	Lucas & Mercanti, LLP	OY E	ower ar warmines			
The following	fees have been s	abmitted:				CALC	ULATIONS	PTO USE
			* * * * * * * * * * * * * * * * * * *		\$300	\$	\$0.00	
	m prepared by IS/ US indicates all c	VUS or the aims satisfi	international preliminar provisions of PCT Arti			\$	\$0.60	
27. Search for the written opinion by IPEA/US Search fee (37 CF) as an International Search previously of	se (37 CFR 1.492 on of the ISA/US of indicates all claim R 1.445(a)(2)) has ational Searching on Report prepare ommunicated to the	(b)) If the Internal is satisfy property been paid Authority. If by an ISA is US by the	ational preliminary examovisions of PCT Article on the international apportunity than the US and a IB.	pilosi pilosi	H(4) \$0 from to the USPTO \$100 fided to the Office or \$400	<i>\$</i>	80.00	
All other situations	OF 25, 26 and		<u>, , , , , , , , , , , , , , , , , , , </u>	9 2 4 9 1111111111	\$508	**************************************	\$0.00	
Additional fee sequence listi	for specification a ing in compliance gram listing in an	and drawing with 37 CFI electronic n mal 50 she Number	is filed in paper over 10 3 1.821(c) or (c) in an election) (37 CFR 1.492 ats of paper or fraction to election additional 50 cereof (round up to a where	())). there 				
- 100 =	0 /50 =		······		× \$250.00	\$	\$0.00	***************************************
			search fee, examination the national slage (37 (\$	\$130.00	
CLAMS	NUMBERF	· · · · · · · · · · · · · · · · · · ·	NUMBER EXTRA		RATE			
Total claims		- 20 ≈	Ü	Х	\$50.00	\$	\$0,00	
Independent claim	8	. 3 m	()	Х	\$200.00	\$	\$0.00	
MULTIPLE DEPE	NOENT CLAIMS	if applicable	e) 🗀	4	\$368.00	\$	00.02	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		T	OTAL OF ABOVE	CA	LCULATIONS =	\$	\$130.00	
[]] Applicant clai	ms small entity st	atus. See 3	7 CFR 1,27, Fees abov	o are	reduced by 1/2.	\$	\$9.90	
	······································			••••	SUBTOTAL =	S	\$130.00	
			glish translation later th	an 3:	0 months from	5	\$0.00	
the earliest claims	o buomy nate (ov	C-17 1,243%		LN	ATIONAL FEE =	\$	\$130.09	·····
Fee for recording	the enclosed assign announciate cov	gnment (37 er stvæt /3	CFR 1.21(h)). The ass 7 CFR 3.28, 3.31). \$40	igna	ent must be	\$	\$0.00	
AN ALLES OF SECTION SECTIONS OF SECTIONS	er – varita fore verker servenser varietie	ener er energen er		e. 44.7,	S ENCLOSED =	ŝ	\$130.00	
						Amou	int to be	\$
						Amou	int to be	S

PTO-1390 (Rev. 09-2006)
Approved for use through 3/31/2007, OMS 0861-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Papenwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OME control number. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. c. It is Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2275 A duplicate copy of this sheet is enclosed. d. 🔯 Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card Information should not be included on this form. Provide credit card information and authorization on PTO-2038, The PTO-2038 should only be mailed or fexed to the USPTO. However, when paying the basic national fee, the PTO-2038 may NOT be faxed to the USPTO. ADVISORY: If filing by EFS-Web, do NOT attach the PTO-2038 form as a PDF along with your EFS-Web submission. Please be advised that this is not recommended and by doing so your credit card information may be displayed via PAIR. To NOTE: Where an appropriate time limit under 37 CFR 1.495 has not bego-met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. SEMD ALL CORRESPONDENCE TO: Customer No. 20311 SIGNATURE LUCAS & MERCANTI, LLP 475 Park Avenue South Michael N. Mercanti New York, New York 10016 MAME Phone: 212-661-8000 Fax: 212-661-8002 33,966 REGISTRATION NUMBER June 8, 2007

DATE

Docket No. PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) (Large Entity) 1017.53202 In Re Application Of: Dale L. Ludwig Examiner Customer No. Group Art Unit | Confirmation No. Application No. Filing Date Unknown 10/555,407 05/03/2004 Unknown. 20311 7544 FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE HUMAN INSULIN-LIKE GROWTH Invention: FACTOR-I RECEPTOR COMMISSIONER FOR PATENTS: This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of ______01/16/2007 ____ in the above-identified application. The requested extension is as follows (check time period desired): ☑ Three months ☐ Four months ☐ Five months Two months One month March 16, 2007 until: June 16, 2007 mon Date Dane The fee for the extension of time is \$1,020 and is to be paid as follows: A check in the amount of the fee is enclosed. The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to 02-2275 Deposit Account No. If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 02-2275 Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Dated: June 8, 2007 Michael N. Mercanti Reg. No. 33,966 LUCAS & MERCANTI, LLP 475 Park Avenue South CERTIFICATE OF ELECTRONIC TRANSMISSION New York, New York 10016 I hereby earlify that this document is being electronically transmitted to the Commissioner for Patents via Phone: 212-661-8000 EFS-Web on June 8, 2007. Fax: 212-661-8002 LUCIS & MERCANT

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

37 CFR 1.56.

My residence, post office address and citizenship are as stated below; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE HUMAN INSULIN-LIKE GROWTH FACTOR-I RECEPTOR

the sp	ecification of which (check only one item below):
	is attached hereto.
X Nove	was filed as United States Application No. 10/555, 507 or as PCT International Application Noon nber 1, 2005 and was amended on (if applicable).
	by state that I have reviewed and understand the contents of the above-identified application, including the claims, as led by any amendment referred to above.
Tacka	owledge the duty to disclose information known to me to be material to the examination of this application as defined by

FOREIGN AND DOMESTIC PRIORITY CLAIMS UNDER 35 USC 119 AND PRIOR FOREIGN/PCT APPLICATIONS

Thereby claim foreign or domestic priority benefits under 35 USC 119 """ or 365(b) for any United States provisional patent application or foreign application(s) for patent or inventor's or plant breeder's rights certificate(s) or under 35 USC 365(a) for any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's or plant breeder's rights certificate(s) or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

COUNTRY/APPLICATION NO.	DATE OF FILING	A Maria Cara Cara Cara Cara Cara Cara Cara	AIMED UNDER
(if PCT, indicate "PCT")	(day/month/year)	35 USC	. 114
60/467,177	01/05/2003	X YES	[]NO
		[]YES	[]NO
		YES	[]NO
Accesses to the second of the		YES	INO

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 USC 120

I hereby claim the benefit under 35 USC 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose material information as defined in 37 CFR 1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PCT/US APPLICATION NO.	PCT/US FILING DATE	PATENTED	PENDING	ABANDONED
PCT/US2004/013852	May 3, 2004	([X]	
		[[]	
			[]	
			3'	

POWER OF ATTORNEY AND CORRESPONDENCE ADDRESS

I hereby appoint the following attorneys at the address listed below to proscepte this application and to transact all business in the U.S. Patent and Trademark Office connected therewith and to receive all correspondence in connection with this application:

Donald C. Lucas, Registration No. 31,275 Michael N. Mercanti, Registration No. 33,965 Laurence Manber, Registration No. 35,597 Otho B. Ross, Registration No. 32,754 Timothy Meade, Registration No. 55,449 Hyun Soon Cho, Registration No. 1.0306 Yandong Chen, Registration No. L0267

ADDRESS:

Lucas & Mercanti, LLP

CUSTOMER NO. 20311

475 Park Avenue South New York, NY 10016 Tel: 212-661-8000 Pax: 212-661-8002

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like 30 made are punishable by fine or imprisonment, or both, under 18 USC 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR IDENTIFICATION AND SIGNATURE

RESIDENCE Randolph, New Jersey	ONTE 5/8/07 CITIZENSHIP United States of American
POST OFFICE ADDRESS 14 Lookout Road, Randolf	oh, New Jersey 07869
FULL NAME OF SECOND INVENTOR	
INVENTOR'S SIGNATURE	DATE
RESIDENCE	CYTIZENSHIP
POST OFFICE ADDRESS	
FULL NAME OF THIRD INVENTOR	MANAGE - TO THE CONTRACTOR OF
INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP
POST OFFICE ADDRESS	AND THE RESIDENCE OF THE PROPERTY OF THE PROPE

Cont...YES[] NO[X]

Electronic Patent	Application Fe	e Transm	ittal			
Application Number:	10555407					
Filing Date:						
Title of Invention:	Fully human antibodies directed against the human insulin-like grow factor-1 receptor					
First Named Inventor/Applicant Name:	Dale L. Ludwig					
Filer:	Michael Nicholas Mercanti					
Attorney Docket Number:	11245/53202					
Filed as Large Entity						
U.S. National Stage under 35 USC 371 F	iling Fees					
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)		
Basic Filing:						
Pages:						
Claims:						
Miscellaneous-Filing:						
Late filing fee for oath or declaration	Late filing fee for oath or declaration 1051 1 130 130					
Petition:						
Patent-Appeals-and-Interference:						
Post-Allowance-and-Post-Issuance:						
Extension-of-Time:						

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension - 3 months with \$0 paid	1253	1	1020	1020
Miscellaneous:				
	Tota	al in USC) (\$)	1150

Electronic A	cknowledgement Receipt
EFS ID:	1855338
Application Number:	10555407
International Application Number:	
Confirmation Number:	7544
Title of Invention:	Fully human antibodies directed against the human insulin-like grow factor-1 receptor
First Named Inventor/Applicant Name:	Dale L. Ludwig
Customer Number:	26646
Filer:	Michael Nicholas Mercanti
Filer Authorized By:	
Attorney Docket Number:	11245/53202
Receipt Date:	08-JUN-2007
Filing Date:	
Time Stamp:	16:52:14
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Sub	mitted with Payment	no
1		7

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multí Part /.zip	Pages p (if appl.)	
1	Documents submitted with 371 Applications	Transmittal.pdf	107001	no	3	
Warnings:			**************************************	<u> </u>		

		Total Files Size (in bytes):	2	68934	*******************************
Information:		•			
Warnings:					
5	Fee Worksheet (PTO-06)	fee-info.pdf	8361	no	2
Information:		1			
Warnings:					
4	Oath or Declaration filed	Declaration.pdf	71105	no	2
Information:					
Warnings:		3			
3	Miscellaneous Incoming Letter	NoticeofMissingParts.pdf	47021	no	2
Information:					
Warnings:					
2	Extension of Time	PetitionforExtension.pdf	35446	no	7
information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Admissioner FOR PATENTS FOR 1466 Admission TEMATER

Newsonspikingson?

APPLICATION NUMBER	FILING or 371(0) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
10/555,407	06/08/2007	1644	4440	11245/53202	56	5

CONFIRMATION NO. 7544

26646 KENYON & KENYON LLP ONE BROADWAY NEW YORK, NY10004 **FILING RECEIPT**

Date Mailed: 08/21/2007

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Dale L. Ludwig, Randolph, NJ;

Power of Attorney: The patent practitioners associated with Customer Number 26646

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/13852 05/03/2004 which claims benefit of 60/467,177 05/01/2003

Foreign Applications

If Required, Foreign Filing License Granted: 08/18/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/555,407

Projected Publication Date: 11/29/2007

Non-Publication Request: No

Early Publication Request: No.

Title

Fully Human Antibodies Directed Against the Human Insulin-Like Growth Factor-1 Receptor

Preliminary Class

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to

espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Exhibit 5

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR FATENTS

P.O. tica 1450
Atexandria, Virginia 22313-1450
texandria, populary

APPLICATION NO.	FELING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO). CONFIRMATION NO.
10/555,407	06/08/2007	Dale L. Ludwig	X-18524	7544
25885 ELI LILLY & (7590		EX	AMINEX
PATENT DIVI	SION		SLANCE	ARD, DAVID J
P.O. BOX 6289 INDIANAPOL	8 IS, IN 46206-6288		ARTINE	PAPER NUMBER
			1643	
			<i></i>	·····
			NOTIFICATION DATE	DELIVERY MODE
			04/28/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patents@lilly.com

		Applicat	ion No.	Applicant(s)	
Office Action Commence		10/555,4	-07	LUDWIG, DALE	
C	Office Action Summary	Examine	r	Art Unit	
		David J.	Blanchard	1643	
The Period for Re	MAILING DATE of this communic	ation appears on th	e cover sheet with the c	orrespondence ad	ldress
WHICHEV - Extensions after SIX (6) - If NO period - Failure to re Any reply re	ENED STATUTORY PERIOD FOR ER IS LONGER, FROM THE MAD firme may be available under the provisions of MONTHS from the mailing date of this communitor reply is specified above, the maximum stationally within the set or extended period for reply we ceived by the Office later than three months after them adjustment. See 37 CFR 1.704(b).	ILING DATE OF T f 37 CFR 1.136(a). In no e nication. Itory period will apply and a ill, by statute, cause the ap	HIS COMMUNICATION vent, however, may a reply be hin vill expire SIX (6) MONTHS from plication to become ABANDONE	∜. nely filed the mailing date of this c D (35 U.S.C. § 133).	
Status					
1) Res	consive to communication(s) filed	on 01 November :	<u>2005</u> .		
* *****	, ,	c) This action is			
3) Sinc	e this application is in condition fo	or allowance excep	t for formal matters, pro	secution as to the	e merits is
close	ed in accordance with the practice	e under <i>Ex parte</i> Q	uayle, 1935 C.D. 11, 45	53 O.G. 213.	
Disposition o	f Claims				
4) Clair	n(s) <u>1-56</u> is/are pending in the ap	plication.			
, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	of the above claim(s)is/are		onsideration.		
	n(s)is/are allowed.				
	n(s) is/are rejected.				
7) Clair	n(s) is/are objected to.				
8)⊠ Clair	n(s) <u>1-56</u> are subject to restriction	n and/or election re	quirement.		
Application P	apers				
9) The s	specification is objected to by the	Examiner.			
*	drawing(s) filed on is/are:) objected to by the I	Examiner.	
	cant may not request that any object		• • • • • • • • • • • • • • • • • • • •		
Repl	acement drawing sheet(s) including t	he correction is requi	red if the drawing(s) is ob	jected to. See 37 Cl	FR 1.121(d).
11) The	eath or declaration is objected to	by the Examiner. N	ote the attached Office	Action or form PT	ΓΟ-152.
Priority under	35 U.S.C. § 119				
a)	Certified copies of the priority d	ocuments have be ocuments have be	en received. en received in Applicati	on No	Stage
* See tl	application from the Internation se attached detailed Office action	·.	1 1 1	ed.	
Attachment(s)					
90000	eferences Cited (PTO-892)		4) Interview Summary	· ·	
44444	raftsperson's Patent Drawing Review (PT Disclosure Statement(s) (PTO/SB/08)	O-948)	Paper No(s)/Mail Da 5) Notice of Informal P		
)/Mail Date		6) Other:		

Art Unit: 1643

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

To have a general inventive concept under PCT rule 13.1, the inventions need to be linked by a special technical feature. The special technical feature recited in claim 1 is an isolated human antibody or fragment thereof that binds IGF-IR and has at least one property selected from the group consisting of (i) inhibits binding of IGF-I or IGF-II to IGF-IR, (ii) neutralizes activation of IGF-IR by IGF-I or IGF-II, (iii) reduces IGF-IR surface receptor expression by at least 80% and (iv) binds to IGF-IR with a K_d of about 3 X 10⁻¹⁰ M⁻¹ or less. In view of this Cohen et al (US Patent 7,037,498, priority to 1/5/01, IDS reference 16 filed 12/23/08) reads on the claim. Cohen et al teach isolated human monoclonal antibodies that bind IGF-IR and inhibit binding of IGF-I or IGF-II to IGF-IR, neutralizes activation of IGF-IR by IGF-I or IGF-II and binds to IGF-IR with a K_d of about 3 X 10⁻¹⁰ M⁻¹ or less (see entire document, particularly cols. 5-6, 8-10, 16-17 and 21). Therefore the technical feature recited in claim 1 is not special. Accordingly the groups are not so linked as to form a single general concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-18 and 23-33, drawn to an isolated human antibody or fragment thereof that binds IGF-IR and pharmaceutical compositions comprising such.

Group II, claims 19-22, drawn to nucleic acid, vectors and host cells encoding human antibody or fragment thereof that binds IGF-IR.

Group III, claims 34 and 36-40, drawn to a method of treating acromegaly comprising administering a human antibody or fragment thereof that binds IGF-IR.

Art Unit: 1643

Group IV, claims 34 and 36-40, drawn to a method of treating retinal neovascularization comprising administering a human antibody or fragment thereof that binds IGF-IR.

Group V, claims 34 and 36-40, drawn to a method of treating psoriasis comprising administering a human antibody or fragment thereof that binds IGF-IR.

Group VI, claims 34, 37 and 41-56, drawn to a method of reducing tumor growth comprising administering a human antibody or fragment thereof that binds IGF-IR.

Claim 35 links inventions III-V. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim, claim 35.

Upon the indication of allowability of the linking claim, the restriction requirement as to the linked inventions shall be withdrawn and any claims depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104. Claims that require all the limitations of an allowable linking claim will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, the allowable linking claim, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

3. The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: As set forth above, in view of the teaching of Cohen

Art Unit: 1643

et al the groups are not so linked as to form a single general concept under PCT Rule 13.1 because the technical feature of claim 1 is not special.

Inventions of Groups I-II represent separate and distinct products which are made by materially different methods, and are used in materially different methods which have different modes of operation, different functions and different effects. The antibody of Group I and the polynucleotide of Group II are all structurally and chemically different from each other. The antibody is raised by immunization while the polynucleotide is made by nucleic acid synthesis. Furthermore, the polynucleotide can be used for hybridization screening and the antibody can be used to immunopurify the antigen, for example. The examination of all groups would require different searches in the U.S. Patent shoes and the scientific literature and would require the consideration of different patentability issues. Thus, the inventions I-II are patentably distinct.

The methods of Inventions III-VI differ in the method objectives. The Invention of Group III recites a method of treating acromegaly comprising administering a human antibody or fragment thereof that binds IGF-IR; Group IV recites a method of treating retinal neovascularization comprising administering a human antibody or fragment thereof that binds IGF-IR; Group V recites a method of treating psoriasis comprising administering a human antibody or fragment thereof that binds IGF-IR and Group VI recites a method of reducing tumor growth comprising administering a human antibody or fragment thereof that binds IGF-IR. Thus, the inventions of Groups III-VI are directed to methods of treating disorders having different etiologies and therapeutic endpoints and are not required one for the other. The examination of all groups would require different searches in the U.S. Patent shoes and the scientific literature and would require the consideration of different patentability issues. Thus, Inventions of Groups III-VI are separate and distinct in having different method objectives and different endpoints and are patentably distinct.

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody of Group I can be used in a materially different

method such as to immunopurify the antigen in addition to the materially different methods of Group III, IV, V and VI.

- 4. Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above <u>and</u> there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:
 - (a) the inventions have acquired a separate status in the art in view of their different classification;
 - (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
 - (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
 - (d) the prior art applicable to one invention would not likely be applicable to another invention;
 - (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either

Art Unit: 1643

instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

5. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Blanchard whose telephone number is (571) 272-0827. The examiner can normally be reached at Monday through Friday from 8:00 AM to 6:00 PM, with alternate Fridays off. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms, can be reached at (571) 272-0832.

The official fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/David J. Blanchard/ Primary Examiner, A.U. 1643

Exhibit 6

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box (450)

Alexandria, Virginia 22313-1450 www.mpto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

23885

7590

(88/E0/2009)

ELI LILLY & COMPANY PATENT DIVISION P.O. BOX 6288 INDIANAPOLIS, IN 46206-6288

EXAMINER BEANCHARD, DAVID J ART UNIT PAPER NUMBER

1(43)

DATE MAILED: 08/10/2009

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/555 407	06/08/2007	Frafe I - Lucimio	V. 1957a	7534

TIPLE OF INVENTION: FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE HUMAN INSULIN-LIKE. GROWTH FACTOR-L RECEPTOR

APPLN, TYPE	SMALL ENTITY	ISSUE FEE DUR	PUBLICATION FRE DUE	PREV. PAID ISSUE FIE	TOTAL FEE(S) DUE	DATE DEE
lanoisivorquon	NO	\$1510	\$300	\$0	\$1810	11/10/2009

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. STATUTORY PERIOD CANNOT BE EXTENDED. $\,$ SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

1. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY states:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B -Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

H. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block I, by (a) specifying a new correspondence address; and/or (b) indicating a senarate "FEE ADDRESS" for

maintenance fee notification CURRENT CORRESPONDEN		ock I for any change of address)	Note Feet	: A certificate of mailin s) Transmittal. This certi	g can only be used fo ficate cannot be used f	or domestic mailings of the or any other accommanying
			pape have	rs. Each additional pape its own certificate of ma	r, such as an assignme iling or transmission.	or domestic mailings of the or any other accompanying of or formal drawing, must
ELI LILLY & C PATENT DIVISI P.O. BOX 6288	ON	/2009	T her State addr	Certificat	e of Mailing or Trans (s) Transmittal is being fficient postage for fic TSSUE FEE address	mission g deposited with the United st class mail in an envelope above, or being facsimile
INDIANAPOLIS.	. IN 46206-6288					(Depositor's rame)
						(Mignantre)
,	.,					(Oste)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTO	DRNEY DOCKET NO.	CONFERMATION NO.
10/555,407	06/08/2007 Dere en verenaans ansa	PROZNEG POPEZOPEN :	Dafe L. Ludwig AGAINST THE HUMAN I	NIGOTE FAS I FASIO Y SECONOS	X-18524 cu dagayar 1 degu	7544 2000 20
			·		·	
APPLN, TYPE	SMALL ENTITY	ISSUE FRE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEB	TOTAL FEE(S) DUE	DATE DEE
Isaoisivouquon	(32)	\$1510	\$300	20	\$1810	11/10/2009
EXAME	GER	ARTEMIT	CLASS-SUBCLASS			
BLANCHARD		1643	530-388150			
1. Change of corresponden CFR 1.363). Change of correspor Address form PTO/SB/	idence address (or Cha 122) attached.	nge of Correspondence	or agents OR, alternative (2) the name of a single	3 registered patent attor	er a 2	
"Fee Address" indica PTO/SB/47; Rev 03-02 Number is required.	anon tor Tree Address or more recent) attach	ingication form ed. Use of a Customer	2 registered patent attor listed, no name will be	neys or agents. If no nar	ne is 3	
PLEASE NOTE: Unles	s an assignee is identi in 37 CFR 3.11. Comp	ified below, no assignee	THE PATENT (print or type data will appear on the profit a substitute for filing and (B) RESIDENCE: (CITY	dent. If an assignce is i assignment.		ocument has been filed for
Please check the appropriate	te assignce category or	categories (will not be p	rinted on the patent):	Individual Corporat	ion or other private gr	oup entity Government
4a. The following fee(5) and lessue Fee Publication Fee (No Advance Order - * 6	small entity discount p	ermitted)	b. Payment of Fee(s): (Plea A check is enclosed. Payment by credit can The Director is hereby overpayment, to Depo	f. Form PTO-2038 is att	ached.	shown above) ficiency, or credit any n extra copy of this form).
 Change in Entity Statu a. Applicant claims 		•	b. Applicant is no long	ger claiming SMALL ESS	TITY status. Sec 37 C	FR 1.27(g)(2).
NOTE: The Issue Fee and interest as shown by the re-	Publication Fee (if requestress of the United Sta	gired) will not be accepte tes Patent and Trademark	ed from anyone other than the Office.	ic applicant; a registered	attorney or agent; or th	se assignee or other party in
Authorized Signature				Date		
Typed or printed name				Registration No.		
Mickandria, vinginia 2231.	\$~ \$400.		on is required to obtain or real 1.14. This collection is estoned depending upon the individual Chief Information Office COMPLETED FORMS TO spond to a collection of information of informatical description of information of informat			thy the USFTO to process) aggathering, preparing, and me you require to complete artment of Commerce, P.O. for Patents, P.O. Box 1450, number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademack Office Adress: COMMISSIONER FOR FATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.nepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFERMATION NO.
10/555,407	06/08/2007	Dale L. Ludwig	X-18524	7544
23885 75	90 (8/B)/26(9)		EXAM	INER
ELITALLY & CO	OMPANY		BEANCHAR	D, DAVID J
PATENT DIVISIO)N		ART UNIT	PAPER NUMBER
P.O. BOX 6288 INDIANAPOLIS, I	IN 46206-6288		1643 DATE MAILED: 08/10/2009	}

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 263 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 263 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 (571)-272-4200.

•••••••••••••••••••••••••••••••••••••••	Application No.	Applicant(s)	•••••
	10/555,407	LUDWIG, DALE L.	
Notice of Allowability	Examiner	Art Unit	
	David J. Blanchard	1643	*****
The MAILING DATE of this communication appeals all claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT Report of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate committee in the committee in	n this application. If not included unication will be mailed in due course. THI	
1. ☑ This communication is responsive to 28 May 2009.			
2. ☑ The allowed claim(s) is/are <u>12-14,23-34, 41-49 and 57-60</u>	(renumbered as claims 1-2	<u>3)</u> .	
 Acknowledgment is made of a claim for foreign priority uses) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received:	e been received. been received in Application	on No	}
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		a reply complying with the requirements	
4. A SUBSTITUTE OATH OR DECLARATION must be submit NFORMAL PATENT APPLICATION (PTO-152) which give			
5. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.		
(a) I including changes required by the Notice of Draftspers	son's Patent Drawing Revie	w (PTO-948) attached	
1) hereto or 2) to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment o	r in the Office action of	
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	# * -		
6. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT			
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☒ Information Disclosure Statements (PTO/SB/08),	6. 🗌 Interview S Paper No.	formal Patent Application ummary (PTO-413), /Mail Date Amendment/Comment	
Paper No./Mail Date <u>See Continuation Sheet</u> 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🔀 Examiner's	Statement of Reasons for Allowance	
/David J Blanchard/ Primary Examiner, Art Unit 1643			

Continuation of Attachment(s) 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date: 12/23/08 (3 pages); 12/23/08 (8 pages).

DETAILED ACTION

Claims 1-11, 15-22, 35-40 and 50-56 are cancelled.
 Claims 12-14, 23-27 and 30 have been amended.
 Claims 57-60 have been added.

2. Claims 12-14, 23-34, 41-49 and 57-60 are pending.

Election/Restrictions

- 3. Applicant's election of the Invention of Group I, claims 12-14, 23-33 and newly added claims 57-60 in the reply filed on 28 may 2009 is acknowledged.
- 4. Claim 34 and 41-49 directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(b), claims 34 and 41-49, directed to the process of making or using the allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Cancelled claims 19-22 (Group II), 34 and 36-40 (Groups III, IV and V), directed to the invention(s) of nucleic acids, vectors and host cells encoding a human antibody or fragment thereof that binds IGF-IR (Group I) and methods of treating acromegaly, retinal neovascularization and psoriasis comprising administering a human antibody or fragment thereof that binds IGF-IR (Groups III, IV and V, respectively) have NOT been rejoined.

Because a claimed invention previously withdrawn from consideration under 37 CFR 1.142 has been rejoined, the restriction requirement among groups I and VI as set forth in the Office action mailed on 28 April 2009 is hereby WITHDRAWN. For clarity, it is noted that the restriction requirement among groups II, III, IV and V as set forth in the Office action mailed on 28 April 2009 is MAINTAINED. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Information Disclosure Statement

5. The Information Disclosure Statement (IDS) filed 23 December 2008 (3 pages) and 23 December 2008 (twelve pages) have been considered by the Examiner. A signed and initialed copy of each IDS is included with the instant Office Action.

Examiner's Amendment

6. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sanjay M. Jivraj on 29 July 2009

The claims are amended as follows:

- 12. (Currently Amended) An isolated human antibody or fragment thereof, which specifically binds to insulin-like growth factor-I receptor (IGF-IR) comprising complementarity-determining region (CDR) regions (CDRs) having the amino acid sequence SEQ ID NO:14 at V_HCDR1, SEQ ID NO:16 at V_HCDR2, SEQ ID NO:18 at V_HCDR3, SEQ ID NO:20 or 26 at V_LCDR1, SEQ ID NO:22 or 28 at V_LCDR2, and SEQ ID NO:24 or 30 at V_LCDR3.
- 13. (Currently Amended) The antibody or antigen-binding fragment thereof of Claim 12, which comprises SEQ ID NO:14 at V_HCDR1, SEQ ID NO:16 at V_HCDR2, SEQ ID NO:18 at V_HCDR3, SEQ ID NO:20 at V_LCDR1, SEQ ID NO:22 at V_LCDR2, and SEQ ID NO:24 at V_LCDR3.
- 14. (Currently Amended) The antibody or antigen binding fragment thereof of Claim 12, which comprises SEQ ID NO:14 at V_HCDR1, SEQ ID NO:16 at V_HCDR2, SEQ ID NO:18 at V_HCDR3, SEQ ID NO:26 at V_LCDR1, SEQ ID NO:28 at V_LCDR2, and SEQ ID NO:30 at V_LCDR3.

Claims 15-22 (Cancelled)

23. (Currently Amended) A pharmaceutical composition comprising the antibody or antibody fragment thereof of Claim 12 and a pharmaceutically acceptable carrier.

24. (Currently Amended) A conjugate comprising the antibody or antibody fragment thereof of Claim 12 linked to a cytotoxic agent.

25. (Currently Amended) A conjugate comprising the antibody or antibody fragment thereof of Claim 12 linked to a label.

26. (Currently Amended) A therapeutic composition effective to inhibit growth of human tumor cells that express IGF-IR, which composition comprises the antibody or antigen binding fragment thereof of Claim 12.

27. (Currently Amended) The therapeutic composition of Claim 26, which further comprises an antineoplastic agent.

28. (Original) The therapeutic composition of Claim 27, wherein the anti-neoplastic agent is an inhibitor of topoisomerase I or topoisomerase II.

29. (Original) The therapeutic composition of Claim 27, wherein the anti-neoplastic agent is selected from the group consisting of irinotecan, camptothecan, and etoposide.

30. (Currently Amended) A therapeutic composition effective to promote regression of human tumors that express IGF-IR, which composition comprises the antibody or antibody fragment thereof of Claim 12.

Page 5

Art Unit: 1643

31. (Original) The therapeutic composition of Claim 30, which further comprises an antineoplastic agent.

- 32. (Original) The therapeutic composition of Claim 31, wherein the anti-neoplastic agent is an inhibitor of topoisomerase I or topoisomerase II.
- 33. (Currently Amended) The therapeutic composition of Claim 31, wherein the anti-neoplastic agent is selected from the group consisting of irinotecan, camptothecan, [[or]] and etoposide.
- 34. (Currently Amended) A method of neutralizing the activation of [[IGF-LR]] <u>IGF-IR</u>, which comprises administering to a mammal an effective amount of the antibody or antibody fragment <u>thereof</u> of Claim 12

Claims 35-40 (Cancelled)

- 41. (Currently Amended) A method of reducing tumor growth which comprises administering to a mammal an effective amount of the antibody or antibody fragment thereof of Claim 12.
- 42. (Original) The method of Claim 41, which further comprises administering an effective amount of an anti-neoplastic agent.
- 43. (Original) The method of Claim 42, wherein the anti-neoplastic agent is an inhibitor of topoisomerase I or topoisomerase II.
- 44. (Original) The method of Claim 42, wherein the anti-neoplastic agent is selected from the group consisting of irinotecan, camptothecan, and etoposide.
- 45. (Currently Amended) A method of promoting tumor regression which comprises administering to a mammal an effective amount of the antibody or antibody fragment thereof of

Claim 12.

46. (Original) The method of Claim 45, which further comprises administering an effective amount of an anti-neoplastic agent.

47. (Original) The method of Claim 46, wherein the anti-neoplastic agent is an inhibitor of topoisomerase I or topoisomerase II.

48. (Original) The method of Claim 46, wherein the anti-neoplastic agent is selected from the group consisting of irinotecan, camptothecan, and etoposide.

49. (Original) The method of any one of Claims 41 to 48, wherein the tumor is a breast tumor, colorectal tumor, pancreatic tumor, ovarian tumor, lung tumor, prostate tumor, bone or soft tissue sarcoma or myeloma.

Claims 50-56 (Cancelled)

- 57. (Currently Amended) An antibody isolated human antibody or fragment thereof comprising [[a]] the heavy chain variable domain represented by of SEQ ID NO:2 and [[a]] the light chain variable domain represented by of SEQ ID NO:6.
- 58. (Currently Amended) An antibody isolated human antibody or fragment thereof comprising [[a]] the heavy chain variable domain represented by of SEQ ID NO:2 and [[a]] the light chain variable domain represented by of SEQ ID NO:10.
- 59. (Currently Amended) The antibody of Claims 57-58 Claims 57 or 58, wherein said antibody has an IgG1 isotype.
- 60. (Currently Amended) A pharmaceutical composition comprising the antibody of Claims 57-59 Claims 57 or 58 and a pharmaceutically acceptable carrier.

Amendments to the specification

On page 1, please delete paragraph [0001] and replace it with the following paragraph:

[0001] This application claims the benefit of United States Provisional Application 60/467,177, filed May 1, 2003 priority of and is a U.S. national phase application of PCT/US2004/013852, filed May 3, 2004, which claims priority of U.S. Provisional Application No. 60/467,177, filed May 1, 2003.

Please Amend Paragraphs 15-26 on pages 6 and 7 as follows;

[0015] Figure 1 depicts the nucleotide sequence of the 2F8 heavy chain variable domain (SEQ ID NO:1).

[0016] Figure 2 depicts the amino acid sequence of the 2F8 heavy chain variable domain. CDRs are in bold and underlined (SEQ ID NO:2).

[0017] Figure 3 depicts the nucleotide sequence of the complete 2F8 heavy chain (underline: secretory signal sequence; italics: IgGl constant region) (SEQ ID NO:3).

[0018] Figure 4 depicts the amino acid sequence of the complete 2F8 heavy chain (underline: secretory signal sequence; bold: CDRs; italics: IgGI constant region) (SEQ ID NO:4).

[0019] Figure 5 depicts the nucleotide sequence of the 2F8 light chain variable domain (SEQ ID NO:5).

[0020] Figure 6 depicts the amino acid sequence of the 2F8 light chain variable domain. CDRs are in bold and underlined (<u>SEQ ID NO:6</u>).

[0021] Figure 7 depicts the nucleotide sequence of the complete 2F8 light chain (underline: secretory signal sequence; italics: IgGI constant region) (SEQ ID NO:7).

[0022] Figure 8 depicts the amino acid sequence of the complete 2F8 light chain (underline: secretory signal sequence; bold: CDRs; italics: IgGI constant region) (SEQ ID NO:8).

[0023] Figure 9 depicts the nucleotide sequence of the A12 light chain variable domain (SEQ ID NO:9).

Art Unit: 1643

[0024] Figure 10 depicts the amino acid sequence of the Al2 light chain variable domain. CDRs are in bold and underlined (SEQ ID NO:10).

[0025] Fig. 11 depicts the nucleotide sequence of the complete A12 light chain (underline: secretory signal sequence; italics: IgGl constant region) (SEQ ID NO:11).

[0026] Figure 12 depicts the amino acid sequence of the complete A12 light chain (underline: secretory signal sequence; bold: CDRs; italics: IgGl constant region) (SEQ ID NO:12).

Please Amend Paragraph 81 on page 18 as follows;

[0081] In another embodiment, the present antibodies, or fragments thereof, can have a heavy chain variable region of SEQ ID NO: 1 SEQ ID NO: 2 and/or a light chain variable region selected from SEQ ID NO:5 or SEQ ID NO:6 SEQ ID NO:6 or SEQ ID NO:10. IMC-A12 is a particularly preferred antibody of the present invention. This antibody has human V_B and V_L framework regions (FWs) as well as CDRs. The V_B variable domain of IMC-A12 (SEQ ID NO:1 SEQ ID NO:2) has three CDRs corresponding to SEQ ID NOs:14, 16, and 18 and the V_L domain (SEQ ID NO:5 SEQ ID NO:10) has three CDRs corresponding to SEQ ID NOS:20, 22, and 24 SEQ ID NOS:26, 28, and 30. IMC-2F8 is another preferred antibody of the present invention. This antibody also has human V_B and V_L framework regions (FWs) and CDRs. The V_B variable domain of IMC-2F8 is identical to the V_B variable domain of IMCA12. The V_L domain of IMC-2F8 (SEQ ID NO:9 SEQ ID NO:6) has three CDRs corresponding to SEQ ID NOS:26, 28, and 30 SEQ ID NOS:20, 22, and 24.

Examiner's Statement of Reasons for Allowance

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Claims 12-14, 23-33 and 57-60 are free of the prior art. The prior art does not teach or fairly suggest an isolated human antibody or fragment thereof comprising the recited heavy and light chain CDR sequences or an antibody comprising the heavy chain variable domain of SEQ ID NO:2 and the light chain variable domain of SEQ ID NO:6 or 10.

Page 9

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Blanchard whose telephone number is (571) 272-0827. The examiner can normally be reached at Monday through Friday from 8:00 AM to 6:00 PM, with alternate Fridays off. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms, can be reached at (571) 272-0832.

The official fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/David J. Blanchard/ Primary Examiner, A.U. 1643

Exhibit 7

PARTB - FERSS TRANSMITTAL.

Complete and send this form, together with applicable fee(s), to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Eux (571)-273-2885

NSTRUCTRING: (Inc.) pposperate. All limites a milestral unions associati naintennaca for matibali	form should be used to seprepositioner including d below or directed offi lons.	s termentating the 1881. 2 die Phiene Letemee Lee ewise in Phiek I, hy ta	s specifying a new control determed nethication of mi determine new control			
	Section of the second section of the second	र्वकार विकास क्षेत्रकारीय पूरवा करेंद्र है कि	7.75XX	A complesse of maling of temponistic libit certific security and some paper. its own vertificate of mali-	र्यस्या वर वर्ष स्थानस्य	e e gamm gan ndi man e mh eiger menitopihing pointing tionnile of the
28925	52686 \$2867.08	3.689			of Halling or Transs	tientare
ELLLILLY & C PATENT DIVIS P.O. BOX 6288			Elbera State addor Acana	thy cestify that this Perfet of Postal Service with suffi- need to the Mail Step 1 antted to the USF100571	gnied di lattimament (kurut postage der tist 1382 di Sett di Sett	general with the United a class must be an enrelight deprended with the United
LIONAKAROM	S, 184 46206-6288			······	······	Spirage, sugar of
				·····	<i></i>	suintes se suinte se suintes se suinte se suintes se suintes se suintes se suintes se suintes se suinte se suintes se suinte se suintes se suin
					·····	
488 A 360 %0	2846 861333	· +++······	ZERST NAMED EVENTOR	ATTS	ENEX (88/8/8) 280	257 SCHEENIGEN
18/535.407	7(865)86939		enemental sitti			**************************************
	······································		CARVET THE BUMANT	~~~~	······	DATE OF E
3828.82886	MAGAMORY	BSCE FEE DEE				
sosprovisiossi		23230		\$8 •	31816	######################################
GAX22	ESES	77901226	CLASSESCIAS			
BLANCHAE	ECIVACIOS	3553	539-3383 50			
Address form PTSSS CF Fee Address ins PTOSBAST Rev 03- Number is required	ikaina (or "Fee Addres Of or more secont) attac L	r indication from hod. Ese al a Custamer	(2) the using of a single registered attracely or a single steered patent and single s	e flem thaving as a memb agent) and the names of a rheye or agents. If no san printed.	85. S.	y M. Jivraj
			THE PATENT (prim or by		daniteas haban ess s	and broken according to the consistence of
recordation as not by	mess an awigner is teen than 33 CPR 3.11. Con	ngga paga, an anggar platan of this Kara is M	At a mereme for time we ame was abben on me b	geg <mark>áuman</mark> e gegáumane	agacines agacin, me o	ed bellt veet sub twamper
(A) WAME OF ASS	3383		(E) SESIDEMEN (CIT	Cand STATE OR COUNT	8%X)	
ImClone, LLC	, , , , , , , , , , , , , , , , , , ,		New York, No	em Zozķ		
France wheek the approx	niste senimes espeinales	n ether that extrapolary	pointos en du potent) — 🚨	Individual Sa Cospexas	ion or other private fr	ada evriji. 🗂 Generaman
	Laor submissidi Na small rulity dissocial Red Copies	(penjard)	· · · · · · · · · · · · · · · · · · ·	rd, Form PTO-XCS8 is att	politoid.	shown above) effectivecy, sy crockt any or extra copy of this form).
	mine Trom stans indicates ma STATE ENTERY and		a 6. Applicant is no los	nger elaiming SMALL EN	TITY 4444. Sec 37 C	¥8 1.27(8×3).
NOTE: The lesses fee a	end Publication For Afford a responsible the Ended S	good, wil not be desing anabest has angel saw	tot loga anyone edner dan. A Chilico	the applicant; a registered	asseniach en vitemet en s	ga staibhea is eagachsagh is
Authorized Stigmen						
Typed or printed us	Sanjay 8.	liyraj	nonnonnonnonnonnonnonnonnonnon	Registration So	61,806	
This collection of information approximation Creatist complete and approximation bugger	mation is appared by 37 minister is apparented by 3 test application from the stices for apparent bases.	CPR LATE The informa S UNC TIL and IT US he LSPTO Time will be surked, disable sent to	ro diado et besipper si mis es si sesteraber sidi (4-1-1-5) sei sub decep paliprepide es dibit acimmental tridi Vester e	retism a francis by the put elimated to take 12 minute vidual cose. Any commen for 128. Patent and Trade con 138. Patent and Trade	olic which is to the Cores to complete, including the complete, including the mank Office, U.S. Ber	ed by the USPICI to provide an numbering, preparing, and line year require to complete outstand of Commerce, P.O. Society, p.O. Book 1400

Ber Birg Bergeria. Virging 2219-1419. Et nitt send bees in typpettedems 10 fils Address. Send fit Commission bet folke. På bog birg. Abrandia. Virging 2215-1489.

Under the Paparasak Reduction Acted 1998, no persons we explical nerespond to a collection of information unless it displays a calld CMR council number

Electronic Pat	ent App	lication Fee	Transm	ittal			
Application Number:	105	555407					
Filing Date:	08-	Jun-2007					
Title of Invention:	l l	FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE HUMAN INSULIN-LIKI GROWTH FACTOR-1 RECEPTOR					
First Named Inventor/Applicant Name:	Dale L. Ludwig						
Filer:	re.Z	njay M. Jivraj/Linda	Durbin				
Attorney Docket Number:	X-1	8524					
Filed as Large Entity							
U.S. National Stage under 35 USC 371 F	iling Fee	S					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)		
Basic Filing:			<u> </u>		<u> </u>		
Pages:							
Claims:	•••••••••••••••••••••••••••••••••••••••			••••••••••••••••			
Miscellaneous-Filing:							
Petition:			•				
Patent-Appeals-and-Interference:							
Post-Allowance-and-Post-Issuance:							
Utility Appl issue fee		1501	1	1510	1510		
Publ. Fee- early, voluntary, or normal		1504	1	300	300		

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
	Tot	al in USD	(\$)	1810

Electronic A	cknowledgement Receipt
EFS ID:	6422201
Application Number:	10555407
International Application Number:	
Confirmation Number:	7544
Title of Invention:	FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE HUMAN INSULIN-LIK GROWTH FACTOR-1 RECEPTOR
First Named Inventor/Applicant Name:	Dale L. Ludwig
Customer Number:	25885
Filer:	Sanjay M. Jivraj/Linda Durbin
Filer Authorized By:	Sanjay M. Jivraj
Attorney Docket Number:	X-18524
Receipt Date:	10-NOV-2009
Filing Date:	08-JUN-2007
Time Stamp:	05:58:15
Application Type:	U.S. National Stage under 35 USC 371

Payment imormation:

yes
Deposit Account
\$1810
6599
050840

File Listing:

Document	Document Description	File Name	File Size(Bytes)/	Multi	Pages
Number	Document Description	rise indine	Message Digest	Part /.zip	(if appl.)

		Total Files Size (in bytes):	33	99441	
Information:					
Warnings:					
-	Z Fee Worksneet (P10-875)		inconstructive en presentation de la presentation d		
2	2 Fee Worksheet (PTO-875)	fee-info.pdf	32309	no.	2
Information	·	*			
Warnings:					
•			441.08497806.1786913466967688274493668 4756		•
1	1 Issue Fee Payment (PTO-858)	X18524lssueFeeTransmittal.pdf	367132	no	1

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Exhibit 8



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Askbess: COMMISSIONER FOR PATENTS P.O. Box 1430 Alexandria, Virgida 22313-1450 www.osplo.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKETNO.	CONFIRMATION NO.
10/555,407	12/29/2009	7638605	X-18524	7544

25888

7590

12/09/2009

ELITILLY & COMPANY PATENT DIVISION P.O. BOX 6288 INDIANAPOLIS, IN 46206-6288

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment is 263 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Dale L. Ludwig, Randolph, NI;

Exhibit 9

Attorney's Docket No.: 14539-0010US1/JF-0101US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mamoru Watanabe Art Unit: 1644

Patent No.: 7,465,444 Examiner: Ilia I. Ouspenski

Issue Date: December 16, 2008 Conf. No.: 3057

Serial No.: 10/472,743 371 date: March 4, 2004

Title : METHODS OF SUPPRESSING OR TREATING AN INFLAMMATORY

BOWEL DISEASE BY ADMINISTERING AN ANTIBODY OR PORTION

THEREOF THAT BINDS TO AILIM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

APPLICATION FOR PATENT TERM ADJUSTMENT UNDER 37 C.F.R. § 1.705(d)

Patentee hereby requests reconsideration of the Patent Term Adjustment (PTA) accorded the above-referenced patent. Reconsideration of the final PTA calculation to increase total PTA from 653 to 1,322 days, is respectfully requested.

REMARKS

(1) Measuring Overlap of "A Delay" and "B Delay"

"A Delays" are defined as delays by the U.S. Patent and Trademark Office (PTO) under 35 U.S.C. § 154(b)(1)(A), which guarantees prompt PTO response. "B Delays" are defined as delays by the PTO under 35 U.S.C. § 154(b)(1)(B), which guarantees no more than three year application pendency. To the extent that the periods of delay overlap, the period of any term adjustment shall not exceed the actual number of days the issuance of the patent was delayed. 35 U.S.C. § 154(b)(2)(A). As outlined in Wyeth et al. v. Jon W. Dudas (U.S. District Court, D.C., CA No. 07-1492, Mem. Op. September 30, 2008), the only way that these periods of time can "overlap" is if they occur on the same day. If an "A delay" occurs on one calendar day and a "B delay" occurs on another calendar day, they do not overlap and 35 U.S.C. § 154(b)(2)(A) does not limit the extension to one day. Id.

CERTIFICATE OF MAILING BY EFS-WEB FILING

Patent No.: 7,465,444

Issued: December 16, 2008

Serial No.: 10/472,743 371 date : March 4, 2004

Page : 2 of 8

The PTA for the instant patent, as currently calculated and shown on the face of the patent, apparently relies on the premise that the application was delayed under 35 U.S.C. § 154(b)(1)(B) before the initial three-year period expired. The Wyeth v. Dudas court determined that this construction cannot be squared with the language of 35 U.S.C. § 154(b)(1)(B), which applies "if the issue of an original patent is delayed due to the failure of the United States Patent and Trademark Office to issue a patent within 3 years." "B delay" begins only after the PTO has failed to issue a patent within three years, not before.

Id.

(2) Measuring "B Delay" for a National Stage Filing under 35 U.S.C. § 371

In addition to and independent of the "overlap" issue addressed above, Patentee respectfully submits that the Office did not apply the proper standard for determining the period of "B Delay" under 35 U.S.C. § 154(b)(1)(B). It is Patentee's understanding that for purposes of calculating "B Delay," the Office measured application pendency as beginning on March 4, 2004, the date on which the application fulfilled the requirements of 35 U.S.C. § 371. However, as detailed below, the relevant statutes and regulations require that when calculating "B Delay" for a national stage filing under 35 U.S.C. § 371, application pendency must be measured from the date that is 30 months from the priority date of the international application (i.e., not from the date on which the application fulfilled the requirements of 35 U.S.C. § 371).

The term of a patent shall, under certain circumstances, be extended if the Office fails to issue a patent within three years after the "actual filing date" of the application.

(B) GUARANTEE OF NO MORE THAN 3-YEAR APPLICATION
PENDENCY.- Subject to the limitations under paragraph (2), if the issue of an original patent is delayed due to the failure of the United States Patent and Trademark Office to issue a patent within 3 years after the actual filing date of the application in the United States ... the term of the patent shall be extended 1 day for each day after the end of that 3-year period until the patent is issued.

35 U.S.C. § 154(b)(1)(B). (emphasis added)

37 C.F.R. § 1.702(b) explains the meaning of the term "actual filing date" as used in 35 U.S.C. § 154(b)(1)(B). As detailed below, PTO delay for a national stage application begins

Patent No.: 7,465,444

Issued: December 16, 2008

Serial No.: 10/472,743 371 date: March 4, 2004

Page : 3 of 8

if the Office fails to issue a patent within three years after the date the national stage "commenced under 35 U.S.C. 371(b) or (f)."

(b) Failure to issue a patent within three years of the actual filing date of the application. Subject to the provisions of 35 U.S.C. 154(b) and this subpart, the term of an original patent shall be adjusted if the issuance of the patent was delayed due to the failure of the Office to issue a patent within three years after the date on which the application was filed under 35 U.S.C. 111(a) or the national stage commenced under 35 U.S.C. 371(b) or (f) in an international application, but not including... 37 C.F.R. § 1.702(b). (emphasis added)

35 U.S.C. §§ 371(b) and (f) refer to the time when a national stage application "commences."

- (b) Subject to subsection (f) of this section, the national stage shall commence with the expiration of the applicable time limit under article 22 (1) or (2), or under article 39 (1)(a) of the treaty. 35 U.S.C. § 371(b). (emphasis added)
- (f) At the express request of the applicant, the national stage of processing may be commenced at any time at which the application is in order for such purpose and the applicable requirements of subsection (c) of this section have been complied with. 35 U.S.C. § 371(f).

35 U.S.C. § 371(f) relates to the situation where an applicant files an express request for early processing of an international application. In the absence of filing such a request, the U.S. national stage commences under the provisions of 35 U.S.C. § 371(b), i.e., with the expiration of the applicable time limit under article 22(1) or (2), or under article 39(1)(a) of the treaty. The term "the treaty" refers to "the Patent Cooperation Treaty done at Washington, on June 19, 1970." See 35 U.S.C. § 351(a).

Consistent with 37 C.F.R. § 1.702(b), MPEP § 2730 states that "[i]n the case of an international application, the phrase 'actual filing date of the application in the United States' [as used in 35 U.S.C. § 154(b)(1)(B)] means the date the national stage commenced under 35 U.S.C. 371(b) or (f)."

Patent No.: 7,465,444

Issued: December 16, 2008

Serial No.: 10/472,743 371 date: March 4, 2004

Page : 4 of 8

The articles of the Patent Cooperation Treaty cited in 35 U.S.C. § 371(b) are reproduced below.

Article 22

Copy, Translation, and Fee, to Designated Offices

- (1) The applicant shall furnish a copy of the international application (unless the communication provided for in Article 20 has already taken place) and a translation thereof (as prescribed), and pay the national fee (if any), to each designated Office not later than at the expiration of 30 months from the priority date. Where the national law of the designated State requires the indication of the name of and other prescribed data concerning the inventor but allows that these indications be furnished at a time later than that of the filing of a national application, the applicant shall, unless they were contained in the request, furnish the said indications to the national Office of or acting for the State not later than at the expiration of 30 months from the priority date. (emphasis added)
- Where the International Searching Authority makes a declaration, under Article 17(2)(a), that no international search report will be established, the time limit for performing the acts referred to in paragraph (1) of this Article shall be the same as that provided for in paragraph (1).

Article 39

Copy, Translation, and Fee, to Elected Offices

(1) (a) If the election of any Contracting State has been effected prior to the expiration of the 19th month from the priority date, the provisions of Article 22 shall not apply to such State and the applicant shall furnish a copy of the international application (unless the communication under Article 20 has already taken place) and a translation thereof (as prescribed), and pay the national fee (if any), to each elected Office not later than at the expiration of 30 months from the priority date. (emphasis added)

"The applicable time limit" referred to in Patent Cooperation Treaty articles 22(1), 22(2), and 39(1)(a) is "the expiration of 30 months from the priority date." As a result, "the expiration of 30 months from the priority date" is the time at which the U.S. national stage commences

Patent No.: 7,465,444

Issued: December 16, 2008

Serial No.: 10/472,743 371 date: March 4, 2004

Page : 5 of 8

under the provisions of 35 U.S.C. § 371(b). This same conclusion as to the timing for commencement of the U.S. national stage is also summarized in MPEP § 1893.01.

Subject to 35 U.S.C. 371(f), commencement of the national stage occurs upon expiration of the applicable time limit under PCT Article 22(1) or (2), or under PCT Article 39(1)(a). See 35 U.S.C. 371(b) and 37 CFR 1.491(a). PCT Articles 22(1), 22(2), and 39(1)(a) provide for a time limit of not later than the expiration of 30 months from the priority date. Thus, in the absence of an express request for early processing of an international application under 35 U.S.C. 371(f) and compliance with the conditions provided therein, the U.S. national stage will commence upon expiration of 30 months from the priority date of the international application. Pursuant to 35 U.S.C. 371(f), the national stage may commence earlier than 30 months from the priority date, provided applicant makes an express request for early processing and has complied with the applicable requirements under 35 U.S.C. 371(e). MPEP § 1893.01. (emphasis added)

In view of the foregoing, the "actual filing date" of a U.S. national stage application filed under 35 U.S.C. § 371, for purposes of calculating "B Delay" under 35 U.S.C. § 154(b)(1)(B) and 37 C.F.R. § 1.702(b), is the date that is 30 months from the priority date of the international application.²

REVIEW OF PATENT TERM ADJUSTMENT CALCULATION

"A Delay"

A first PTO action was due on or before May 4, 2005 (the date that is fourteen months after March 4, 2004, the date on which the application fulfilled the requirements of 35 U.S.C. § 371). The PTO mailed the first non-final Office Action on October 24, 2006, thereby according a PTO Delay of 538 days. Patentee does not dispute the PTO's calculation for this "A Delay" from May 5, 2005 (the day after the date that is fourteen months after the date on

² In contrast to reliance on "the expiration of 30 months from the priority date" for measuring "B Delay," the beginning of the relevant period for purposes of calculating "A Delay" is the date on which an international application fulfills the requirements of 35 U.S.C. § 371. See 35 U.S.C. § 154(b)(1)(A)(i)(II) and 37 C.F.R. § 1.702(a)(1).

Patent No.: 7,465,444

Issued : December 16, 2008

Serial No.: 10/472,743 371 date: March 4, 2004

Page : 6 of 8

which the application fulfilled the requirements of 35 U.S.C. § 371), to October 24, 2006. See 37 C.F.R. §§ 1.702(a)(1) and 1.703(a)(1).

In view of the period of "A Delay" detailed above, the total "A Delay" for this patent should be calculated as 538 days.

"B Delay"

The present application is a national stage filing under 35 U.S.C. § 371 of international application number PCT/JP02/01361, filed February 18, 2002, which claims the benefit of priority of Japanese application number 2001-89158, filed March 27, 2001, and Japanese application number 2002-19291, filed January 29, 2002.

The national stage for the present application "commenced" under the provisions of 35 U.S.C. § 371(b), i.e., upon expiration of 30 months from the priority date of the international application.³ As a result, the date that the national stage commenced was September 27, 2003 (i.e., 30 months from the priority date of March 27, 2001).

The period beginning on September 28, 2006 (the day after the date that is three years after September 27, 2003, the date that the national stage commenced), and ending December 16, 2008 (the date the patent was issued), is 811 days in length.

In view of the period of "B Delay" detailed above, the total "B Delay" for this patent should be calculated as 811 days. The PTO calculated 115 days of delay for issuance of a patent more than three years after filing. Patentee respectfully submits that the PTO's calculation of this "B Delay" is incorrect and that the correct PTO Delay for issuance beyond three years from filing is 811 days. See 37 C.F.R. §§ 1.702(b) and 1.703(b).

³ No request for early processing under 35 U.S.C. § 371(f) was filed for the present application.

Patent No.: 7,465,444

Issued: December 16, 2008

Serial No.: 10/472,743 371 date: March 4, 2004

Page: 7 of 8

Overlap of "A Delay" and "B Delay"

As detailed above, "A Delay" accumulated during the following period:

May 5, 2005, to October 24, 2006.

As detailed above, "B Delay" accumulated during the following period:

September 28, 2006, to December 16, 2008.

The "A Delay" and the "B Delay" overlap (i.e., occur on the same calendar day) for a total of 27 days, from September 28, 2006, to October 24, 2006.

Applicant Delay

There were no circumstances constituting a failure to engage in reasonable efforts to conclude processing or examination of the application as set forth 37 C.F.R. § 1.704.

Terminal Disclaimer

This patent is not subject to a terminal disclaimer.

Conclusion

In consideration of the events described above, Patentee believes the PTA calculation of 653 days is incorrect. As such, Patentee respectfully requests reconsideration of the PTA in the following manner:

- 1) Total PTO Delay should be calculated as 1,322 days (i.e., the sum of 538 days of "A Delay" and 811 days of "B Delay" minus the 27 days of overlap);
 - 2) Total Applicant Delay should be calculated as 0 days; and
 - 3) Total PTA should be calculated as 1,322 days.

Patent No.: 7,465,444

Issued : December 16, 2008

Serial No.: 10/472,743 371 date : March 4, 2004

Page : 8 of 8

Please apply the fee of \$200 required under 37 C.F.R. § 1.18(e) and any other required charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket Number 14539-0010US1.

Respectfully submitted,

Date: January 8,2009

Jack Brennan Reg. No. 47,443

Fish & Richardson P.C. Citigroup Center 52nd Floor 153 East 53rd Street

New York, New York 10022-4611

Telephone: (212) 765-5070 Facsimile: (877) 769-7945

30464624.doc



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 www.uspto.gov

FISH & RICHARDSON P.C. P.O. BOX 1022 MINNEAPOLIS MN 55440-1022

COPY MAILED

JUN 1 6 2009

In re Patent No. 7,465,444

Mamoru Watanabe

Issue Date: December 16, 2008 Application No. 10/472,743

Filed: March 24, 2004

Attorney Docket No. 14539-

010US1

Title: Methods Of Suppressing or Treating An Inflammatory Bowel Disease by Administering an Antibody or Portion Thereof That Binds To Ailim

OFFICE OF PETITIONS

: DECISION ON REQUEST FOR

: RECONSIDERATION OF

: PATENT TERM ADJUSTMENT

This is a decision on the "APPLICATION FOR PATENT TERM ADJUSTMENT UNDER 37 C.F.R. § 1.705(d)," filed January 8, 2009.

The application for reconsideration of patent term adjustment is GRANTED to the extent indicated herein.

The above-identified application matured into U.S. Patent No. 7,465,444 on December 16, 2008. The patent issued with a patent term adjustment of 653 days. This request for reconsideration of patent term adjustment was timely filed within two months of the issue date of the patent. See, 37 CFR 1.705(d). Patentees request that the patent term adjustment determination for the above-identified patent be changed from 653 days to 1322 days.

Patentee requests recalculation of the patent term adjustment based on the decision in Wyeth v. Dudas, 580 F. Supp. 2d 138, 88 U.S.P.Q. 2d 1538 (D.D.C. 2008). Patentees assert that pursuant to Wyeth, a PTO delay under 35 U.S.C. 154(b)(1)(A) overlaps with a delay under 35 U.S.C. 154(b)(1)(B) only if the delays occur on the same day.

The petition submitted by patentee sets forth a period of adjustment for Office delays totaling 1349 days (Three Year Delay under 37 CFR 1.703(b) of 811 days plus a period of adjustment due to examination delay pursuant to 37 CFR 1.702(a) of 538 days). The petition also sets forth an overlap of 27 days. The petition reflects a reduction of patent term adjustment totaling "0" days for applicant's failure to engage in reasonable efforts to conclude prosecution pursuant to 37 CFR 1.704. Thus, patentee asserts entitlement to an overall adjustment of 1322 days (1349(811+538)) days for Office delay less 27 days for overlap).

Patentee's petition does not dispute the adjustments under 37 CFR 1.702(a) totaling 538 days. Patentee's petition acknowledges the "0" reductions for applicant's failure to engage in reasonable efforts to conclude prosecution pursuant to 37 CFR 1.704. These reductions total 0 days.

Under 37 CFR 1.703(f), patentees are entitled to a period of patent term adjustment equal to the period of delays based on the grounds set forth in 37 CFR 1.702 reduced by the period of time during which patentees failed to engage in reasonable efforts to conclude prosecution pursuant to 37 CFR 1.704.

The Office agrees that as of the issuance of the patent on December 16, 2008, the application was pending three years and 811 days after the commencement date (September 27, 2003) pursuant to 37 CFR 1.371. The Office agrees that because certain actions were not taken within specified time frames, the patent is entitled to an adjustment of 538 days pursuant to 37 CFR 1.702(a). At issue is whether patentees should accrue an additional 811 days of patent term adjustment for the Office taking in excess of three years to issue the patent, as well as 538 days for Office failure to take a certain action within a specified time frame (or examination delay).

The Office contends that 538 of the 811 days overlap. Patentee's calculation of the period of overlap is inconsistent with the Office's interpretation of this provision. 35 U.S.C. 154(b)(2)(A) limits the adjustment of patent term, as follows:

To the extent that the periods of delay attributable to grounds specified in paragraph (1) overlap, the period of any adjustment granted under this subsection shall not exceed the actual number of days the issuance of the

patent was delayed.

Likewise, 35 CFR 1.703(f) provides that:

To the extent that periods of delay attributable to the grounds specified in § 1.702 overlap, the period of adjustment granted under this section shall not exceed the actual number of days the issuance of the patent was delayed.

As explained in Explanation of 37 CFR 1.703(f) and of the United States Patent and Trademark Office Interpretation of 35 U.S.C. 154(b)(2)(A), 69 Fed. Reg. 34283 (June 21, 2004), the Office interprets 35 U.S.C. 154(b)(2)(A) as permitting either patent term adjustment under 35 U.S.C. 154(b)(1)(A)(i)-(iv), or patent term adjustment under 35 U.S.C. 154(b)(1)(B), but not as permitting patent term adjustment under both 35 U.S.C. 154(b)(1)(A)(i)-(iv) and 154(b)(1)(B). Accordingly, the Office implements the overlap provision as follows:

If an application is entitled to an adjustment under 35 U.S.C. 154(b)(1)(B), the entire period during which the application was pending (except for periods excluded under 35 U.S.C. 154(b)(1)(B)(i)-(iii)), and not just the period beginning three years after the actual filing date of the application or the national stage commenced under 35 U.S.C. 371(b) or (f), is the period of delay under 35 U.S.C. 154(b)(1)(B) in determining whether periods of delay overlap under 35 U.S.C. 154(b)(2)(A). Thus, any days of delay for Office issuance of the patent more than 3 years after the filing or commencement date of the application, which overlap with the days of patent term adjustment accorded prior to the issuance of the patent will not result in any additional patent term adjustment. See, 35 U.S.C. 154(b)(1)(B), 35 U.S.C. 154(b)(2)(A), and 37 CFR § 1.703(f). See, Changes to Implement Patent Term Adjustment Under Twenty Year Term; Final Rule, 65 Fed. Reg. 56366 (Sept. 18, 2000). See, also, Revision of Patent Term Extension and Patent Term Adjustment Provisions; Final Rule, 69 Fed. Reg. 21704 (April 22, 2004), 1282 Off. Gaz. Pat. Office 100 (May 18, 2004). See, also, Explanation of 37 CFR 1.703(f) and of the United States Patent and Trademark Office Interpretation of 35 U.S.C. 154(b)(2)(A), 69 Fed. Reg. 34283 (June 21, 2004).

The current wording of § 1.703(f) was revised in response to the misinterpretation of this provision by a number of Patentees. The rule was slightly revised to more closely track the corresponding language of 35 U.S.C. 154(b)(2)(A). The relevant portion differs only to the extent that the statute refers back to provisions of the statute whereas the rule refers back to sections of the rule. This was not a substantive change to the rule nor did it reflect a change of the Office's interpretation of 35 U.S.C. 154(b)(2)(A). As stated in the Explanation of 37 CFR 1.703(f) and of the United States Patent and Trademark Office Interpretation of 35 U.S.C. 154(b)(2)(A), the Office has consistently taken the position that if an application is entitled to an adjustment under the three-year pendency provision of 35 U.S.C. 154(b)(1)(B), the entire period during which the application was pending before the Office (except for periods excluded under 35 U.S.C. 154(b)(1)(B)(i)-(iii)), and not just the period beginning three years after the actual filing date of the application or the national stage commenced under 35 U.S.C. 371(b) or (f), is the relevant period under 35 U.S.C. 154(b)(1)(B) in determining whether periods of delay "overlap" under 35 U.S.C. 154(b)(2)(A).

This interpretation is consistent with the statute. Taken together the statute and rule provide that to the extent that periods of delay attributable to grounds specified in 35 U.S.C. 154(b)(1) and in corresponding § 1.702 overlap, the period of adjustment granted shall not exceed the actual number of days the issuance of the patent was delayed. The grounds specified in these sections cover the A) guarantee of prompt Patent and Trademark Office responses, B) guarantee of no more than 3-year application pendency, and C) guarantee or adjustments for delays due to interference, secrecy orders and appeals. A section by section analysis of 35 U.S.C. 154(b)(2)(A) specifically provides that:

Section 4402 imposes limitations on restoration of term. In general, pursuant to [35 U.S.C.] 154(b)(2)(A)-(C), total adjustments granted for restorations under [35 U.S.C. 154](b)(1) are reduced as follows: (1) To the extent that there are multiple grounds for extending the term of a patent that may exist simultaneously (e.g., delay due to a secrecy order under [35 U.S.C.] 181 and administrative delay under [35 U.S.C.] 154(b)(1)(A)), the term should not be extended for each ground of delay but only for the

actual number of days that the issuance of a patent was delayed; See 145 Cong. Rec. S14,7181

As such, the period for over three-year pendency does not overlap only to the extent that the actual dates in the period beginning three years after the date on which the application commenced overlap with the actual dates in the periods for failure of the Office to take action within specified time frames. In other words, consideration of the overlap does not begin three years after the commencement date of the application.

In this instance, the relevant period under 35 U.S.C. 154(b)(1)(B) in determining whether periods of delay "overlap" under 35 U.S.C. 154(b)(2)(A) is the entire period during which the application was pending before the Office

The application actually issued three years and 811 days after its commencement date. The Office did not delay 538 days and then delay an additional 811 days.

Accordingly, the proper adjustment of 811 days of patent term adjustment (not 538 days and 811 days) should have been entered because the period of delay of 538 of 811 days attributable to the delay in the issuance of the patent overlaps with the adjustment of 538 days attributable to grounds specified in § 1.702(a). Entry of both periods is not warranted. Thus, 811 days is determined to be the actual number of days that the issuance of the patent was delayed.

In view thereof, the patent term adjustment indicated in the patent should have been eight hundred eleven (811) days.

Receipt of the \$200.00 fee set forth in 37 CFR 1.18(e) is acknowledged. No additional fees are required.

Patentees are given THIRTY (30) DAYS or ONE (1) MONTH, whichever is longer, from the mail date of this decision to respond to

The AIPA is title IV of the Intellectual Property and Communications Omnibus Reform Act of 1999 (S. 1948), which was incorporated and enacted as law as part of Pub. L. 106-113. The Conference Report for H.R. 3194, 106th Cong. 1st Sess. (1999), which resulted in Pub. L. 106-113, does not contain any discussion (other than the incorporated language) of S. 1948. A section-by-section analysis of S. 1948, however, was printed in the Congressional Record at the request of Senator Lott, See 145 Cong. Rec. S14,708-26 (1999) (daily ed. Nov. 17, 1999).

this decision. No extensions of time will be granted under § 1.136.

The application will be forwarded to the Certificates of Correction Branch for issuance of a certificate of correction in order to rectify this error. See 35 U.S.C. § 254 and 37 CFR§ 1.322. After the thirty day time period has elapsed, the Office will sua sponte issue a certificate of correction indicating that the term of the above-identified patent is extended or adjusted by eight hundred eleven (811) days.

Kery Fries

Senior Legal Advisor Attorney
Office of Patent Legal Administration

Cc: Fish & Richardson P.C.
Citigroup Center
52nd Floor
153 East 53rd Street
New York, NY 10022-4611